Drugs, Doses, and Durations of Intraperitoneal Chemotherapy: Standardising HIPEC and EPIC for Colorectal, Appendiceal, Gastric, Ovarian Peritoneal Surface Malignancies and Peritoneal Mesothelioma

Int J Hyperthermia. 2017 Aug;33(5):582-592. doi: 10.1080/02656736.2017.1291999.

Abstract

Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynaecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardisation regarding the CRS, we are still lacking a much-needed standardisation amongst the various IP chemotherapy treatment modalities used today in clinical practice. Pharmacologic evidence should be generated to answer important questions raised by the myriad of variables associated with IP chemotherapy.

Keywords: BIC; EPIC; HIPEC; Peritoneal surface malignancy.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Humans
  • Hyperthermia, Induced / methods*
  • Mesothelioma / drug therapy*
  • Mesothelioma / pathology
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Peritoneal Neoplasms / drug therapy*
  • Peritoneal Neoplasms / pathology